• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis.

作者信息

Esposito Maria, De Berardinis Andrea, Totaro Rocco, Fargnoli Maria Concetta

机构信息

Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Department of Neurology, Multiple Sclerosis Center, San Salvatore Hospital, L'Aquila, Italy.

出版信息

JAAD Case Rep. 2022 Nov 5;31:1-5. doi: 10.1016/j.jdcr.2022.10.031. eCollection 2023 Jan.

DOI:10.1016/j.jdcr.2022.10.031
PMID:36458235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9706390/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc0b/9706390/61c14daba9c1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc0b/9706390/61c14daba9c1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc0b/9706390/61c14daba9c1/gr1.jpg

相似文献

1
Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis.度普利尤单抗用于中重度特应性皮炎和多发性硬化症患者。
JAAD Case Rep. 2022 Nov 5;31:1-5. doi: 10.1016/j.jdcr.2022.10.031. eCollection 2023 Jan.
2
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
3
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.度普利尤单抗为未达到研究者全球评估（IGA）的清除或几乎清除的特应性皮炎患者提供了重要的临床获益：两项 III 期临床试验数据的汇总分析。
Br J Dermatol. 2019 Jul;181(1):80-87. doi: 10.1111/bjd.17791. Epub 2019 Apr 11.
4
Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study.度普利尤单抗改善中重度特应性皮炎患儿和青少年的临床评分：一项真实世界、单中心研究。
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2378-2385. doi: 10.1016/j.jaip.2022.06.014. Epub 2022 Jun 24.
5
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
6
Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.英国通过早期药物获取计划（EAMS）接受度普利尤单抗治疗的特应性皮炎（AD）患者的治疗结局。
Ulster Med J. 2021 May;90(2):70-76. Epub 2021 Jul 8.
7
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎成人患者。
N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.
8
Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study.度普利尤单抗对台湾中重度特应性皮炎成年患者不同表型的疗效：一项真实世界研究
J Clin Med. 2022 Oct 21;11(20):6209. doi: 10.3390/jcm11206209.
9
Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.特应性皮炎青少年和成人患者的湿疹面积和严重程度指数（EASI）、改良 EASI、特应性皮炎评分（SCORAD）、客观 SCORAD、特应性皮炎严重程度指数和体表面积严重程度分层。
Br J Dermatol. 2017 Nov;177(5):1316-1321. doi: 10.1111/bjd.15641. Epub 2017 Oct 1.
10
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的临床意义：一项随机临床试验的事后分析。
Am J Clin Dermatol. 2020 Feb;21(1):119-131. doi: 10.1007/s40257-019-00478-y.

引用本文的文献

1
Dupilumab, a Novel Treatment for Peripheral Neuropathy: A Case Series.度普利尤单抗治疗周围神经病变的病例系列：一项新疗法
Dermatol Ther (Heidelb). 2025 Jun;15(6):1569-1577. doi: 10.1007/s13555-025-01415-0. Epub 2025 Apr 24.
2
A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities.一项关于度普利尤单抗治疗特应性皮炎患者的真实世界研究，其中包括患有恶性肿瘤和其他内科合并症的患者。
JAAD Int. 2024 Jan 17;15:5-11. doi: 10.1016/j.jdin.2024.01.002. eCollection 2024 Jun.

本文引用的文献

1
Relapsing-remitting multiple sclerosis arising in a patient with atopic dermatitis on dupilumab.在使用度普利尤单抗治疗特应性皮炎的患者中出现复发缓解型多发性硬化症。
JAAD Case Rep. 2021 Jul 15;15:33-35. doi: 10.1016/j.jdcr.2021.07.003. eCollection 2021 Sep.
2
Atopic dermatitis.特应性皮炎。
Lancet. 2020 Aug 1;396(10247):345-360. doi: 10.1016/S0140-6736(20)31286-1.
3
Treatment of Multiple Sclerosis: A Review.多发性硬化症的治疗：综述
Am J Med. 2020 Dec;133(12):1380-1390.e2. doi: 10.1016/j.amjmed.2020.05.049. Epub 2020 Jul 17.
4
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗 6 至 11 岁重度特应性皮炎儿童的疗效和安全性：一项随机、双盲、安慰剂对照的 3 期临床试验。
J Am Acad Dermatol. 2020 Nov;83(5):1282-1293. doi: 10.1016/j.jaad.2020.06.054. Epub 2020 Jun 20.
5
Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States.美国一家三级医疗中心的度普利尤单抗药物留存率、治疗失败情况及保险获批情况。
J Am Acad Dermatol. 2020 Apr;82(4):1023-1024. doi: 10.1016/j.jaad.2019.12.034. Epub 2019 Dec 20.
6
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的疗效和安全性：一项 3 期随机临床试验。
JAMA Dermatol. 2020 Jan 1;156(1):44-56. doi: 10.1001/jamadermatol.2019.3336.
7
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.成人中重度特应性皮炎患者使用度普利尤单抗的有效性和安全性的真实世界经验。
J Dermatolog Treat. 2021 Aug;32(5):507-513. doi: 10.1080/09546634.2019.1682503. Epub 2019 Oct 28.
8
Comorbidities and the impact of atopic dermatitis.共病和特应性皮炎的影响。
Ann Allergy Asthma Immunol. 2019 Aug;123(2):144-151. doi: 10.1016/j.anai.2019.04.020. Epub 2019 Apr 26.
9
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎成人患者。
N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.
10
Teriflunomide and its mechanism of action in multiple sclerosis.特立氟胺及其在多发性硬化症中的作用机制。
Drugs. 2014 Apr;74(6):659-74. doi: 10.1007/s40265-014-0212-x.